Vaccine by Sinopharm's Wuhan institute becomes third to enter market

Download

An inactivated COVID-19 vaccine developed by Sinopharm's Wuhan institute became the third vaccine to enter the market in China on Sunday, Hubei Daily reported.

The institute has a production capacity of 100 million doses per year, the report said.

Open in CGTN APP for better experience

Search Trends